Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Brumar89 who wrote (554686)	3/12/2010 7:44:18 PM
From: J_F_Shepard	Read Replies (3) \| Respond to of 1576401

Sounds like he did pretty well with Canadian care....Why is Mayo billing him for 108K? He didn't pay anything in Canada for his first 10 years... "Ten years ago, when first diagnosed with a glioblastoma multiforme brain tumour (GBM), Kent Pankow was given five years to live. After beating it down once, however, with his first surgery having been performed in Alberta, he spent nearly seven years in remission until the cancer’s return in 2008." Your RW link said he had to get in a que to get an MRI which is false..... "The Cross Cancer institute ordered an urgent MRI on Sept 10th 2009. It revealed that there are currently 3 tumours in Kent’s right frontal lobe, covering a 10 cm area which has expanded into the centre of his brain. The Mayo Clinic has access to drugs that are not yet approved in Canada and they have surgeons who can conduct motor mapping to reduce the risks associated with brain surgery. Kent's surgery will take place in an MRI surgical suite under the capable hands of Dr. Ian Parney and team. The Mayo Clinic in Rochester Minnesota is ranked No.1 in Neurology and Neurosurgery in the U.S. News & World Report Best Hospitals rankings." His tumor's were not completely removed at Mayo...their desperate chemo approach is to use Avastin (a black bordered drug in the US) and not approved in Canada. "According to Genentech, the FDA based its approval on two clinical trials that together included more than 200 glioblastoma patients. Between 20% and 26% of patients showed a tumor response to Avastin that typically lasted for about four months. According to Genentech, adverse events seen in Avastin's glioblastoma trials were in line with the drug's known risks, which include developing gastrointestinal perforations (tears in the stomach or colon), complications with wound healing, and severe or fatal bleeding."